In contrast to full PPARγ agonists, partial PPARγ agonists mitigate insulin resistance and hyperglycemia in rodent models of obesity without increasing adiposity and cardiac weight [10]. The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.